by sfrazee | Oct 26, 2022 | White Papers
This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion...
by jmanor | Aug 12, 2022 | White Papers
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but also the costs of preventing the disease. This paper assesses how new medical innovations for COVID-19—specifically...
by jmanor | Aug 11, 2022 | White Papers
From April 2020 through at least the end of 2021, Americans died from non-Covid causes at an average annual rate 97,000 in excess of previous trends. Hypertension and heart disease deaths combined were elevated 32,000. Diabetes or obesity, drug-induced causes, and...
by jmanor | Aug 3, 2022 | White Papers
This paper reviews the evidence covering the impact of biopharmaceuticals on the level and growth of total health care costs. The primary source of spending in health care is on labor, such as doctors, nurses or assistants, which makes up over 70% of overall spending,...
by susuguo | Jul 1, 2022 | White Papers
In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent...
by jmanor | Jun 27, 2022 | White Papers
In February 2022, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and stated that one of its objectives is to reduce cancer mortality by 50% over the next 25 years. Currently, there is already a very large amount of...
